All News

Patients with metastatic colorectal cancer who desire better disease control are best served with trifluridine/tipiracil plus bevacizumab, according to Marwan G. Fakih, MD.

A predetermined change control plan was authorized as part of the premarket approval, allowing for AI enhancements without the need for FDA oversight.

If approved, iberdomide plus daratumumab/dexamethasone would offer patients more choices, according to Sagar Lonial, MD, FACP, FASCO.

Data from a phase 1b/2 study may support further assessment of AZD0120 in earlier treatment settings for patients with multiple myeloma.

Marwan G. Fakih, MD, discussed many of the factors he considers when deciding on a treatment for a patient with metastatic colorectal cancer.

Oncologists discussed key abstracts assessing AI models for treatment selection, AKT inhibition, and PARP inhibition in specific prostate cancer types.

In the phase 3 neoCARHP trial, THP showed noninferior pathologic complete response rates compared with TCbHP in patients with HER2-positive breast cancer.

A White Paper showed there was no convincing evidence that GLP-1 RAs cause papillary, follicular, or Oncocytic thyroid cancers.

Diane Simeone, MD, explained that shifting diagnosis toward earlier stages could raise the pancreatic cancer survival rate from 13% to over 80% for certain patients.

The FDA tentatively approved PNT2003, a radioequivalent to lutetium Lu 177 dotatate, for adults with GEP-NETs based on comparable efficacy and safety data.

Updated results from the phase 3 KEYNOTE-B96 trial revealed that pembrolizumab plus paclitaxel with or without bevacizumab improved OS in all comers.

The FDA has set a Prescription Drug User Fee Act date for the third quarter of 2026 for approving rusfertide for polycythemia vera.

Daniel C. McFarland, DO, and Boris Kiselev, MD, highlight the need for oncologists to recognize and address depression for patients with cancer.

The majority of patients experiencing recurrence of their MIBC within 6 months of study start had high concentrations of ctDNA at baseline.

Several differences arise between community oncology centers and institutional oncology centers regarding the tools available and requirements of patients with cancer.

The triplet regimen also improved health-related quality of life and pain compared with ADT plus ARPI alone in patients with metastatic hormone-sensitive prostate cancer.

An effective regimen that partly incorporates oral therapy may be favorable from a patient convenience perspective, said Sagar Lonial, MD, FACP, FASCO.

SBRT was considered safe among patients with advanced renal cell carcinoma when added to the immunotherapy combination.

CAR T-cell therapies and T-cell engagers may produce an “exciting” benefit on the radiosensitization of prostate tumors.

Patrick Borgen, MD, discussed using ctDNA for “molecular interception” to de-escalate surgery and minimize AEs in biology-driven breast cancer care.

Based on findings from LITESPARK-11, belzutifan/lenvatinib may represent a new option in previously treated renal cell carcinoma.

The phase 2 study aimed to compare the safety of pembrolizumab and radiation with or without olaparib in this high-risk population.

Despite differences in treatment tolerance across different RCC subgroups, survival outcomes were similar in a retrospective study.

Data from PEACE-2 may challenge the current definition of "very high-risk" localized prostate cancer without nodal disease involvement.

Sarah Poland, MD, discussed the divergence between the IMpassion130 and IMpassion131 trials and the critical role of confirmatory trials in oncology.

Data from RETAIN-1 and RETAIN-2 show the chemoradiotherapy or BCG may remain viable options in those with ctDNA negativity but evidence of local disease.

Phase 3 data support perioperative enfortumab vedotin plus pembrolizumab as a novel treatment option in MIBC regardless of eligibility for cisplatin.

The expansion of clinical trials evaluating proton-based radiotherapy could elucidate its benefits and increase its access across the US.

Retrospective data show that relapse-free survival outcomes were worse for patients with MDS/MPN compared with those who had other types of MDS.

Often, patients in middle-income settings, are the patients who are impacted most by insurance deductibles, according to Loretta Nastoupil, MD.